Hives News and Research RSS Feed - Hives News and Research

Hives (or Urticaria) are a kind of skin rash notable for dark red, raised, itchy bumps. Hives are frequently caused by allergic reactions; however, there are many non-allergic causes.
FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved the Company's supplemental new drug application for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE. [More]
New legislation to provide epinephrine to children with severe food allergies in schools

New legislation to provide epinephrine to children with severe food allergies in schools

An act recently signed by President Obama will make it easier to provide epinephrine to children with severe food allergies in schools, even without a prescription. Physicians at Nationwide Children's Hospital hope the act will encourage the remaining 20 states to pass legislation, incentivizing and, in some cases, requiring that schools to have this medication available for all students since up to 6 percent of children in the United States are now diagnosed with a food allergy. [More]
Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes. [More]
Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy. [More]
Intelliject to be recognized with George DiDomizio Industry Award

Intelliject to be recognized with George DiDomizio Industry Award

The Institute for Safe Medication Practices has announced that this year's George DiDomizio Industry Award is being presented to Intelliject, Inc. for pioneering advances in drug/device combination products with the Auvi-Q epinephrine auto-injector (also known as Allerject™ in Canada). Auvi-Q is the first auto-injector with audio as well as visual cues for the emergency treatment of life-threatening allergic reactions. [More]
Life-saving bone marrow transplants may also cure peanut allergies

Life-saving bone marrow transplants may also cure peanut allergies

Not only can bone marrow transplants be life-saving for children with acute lymphocytic leukemia, they may also cure peanut allergies. According to research presented during the American College of Allergy, Asthma and Immunology's Annual Scientific Meeting, a 10-year-old boy no longer had a peanut allergy after undergoing a bone marrow transplant. [More]
Anaphylaxis due to shrimp allergy is less than 8% in children

Anaphylaxis due to shrimp allergy is less than 8% in children

Anaphylaxis is a severe allergic reaction that can be life-threatening. Shellfish is the third most common food allergy to cause anaphylaxis. [More]
People with gelatin allergy can have reaction from flu vaccinations

People with gelatin allergy can have reaction from flu vaccinations

Do marshmallows make your tongue swell? Gummy bears make you itchy? If you've answered yes and are allergic to gelatin, you will want to take some precautions when getting the flu shot. [More]
European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease. [More]
FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted and filed the company's supplemental Biologics License Application for subcutaneous use of Xolair (omalizumab) in people with Chronic Idiopathic Urticaria who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses. [More]
Selenium in plants causes mortality and delays development in honey bee, say researchers

Selenium in plants causes mortality and delays development in honey bee, say researchers

Traditionally, honey bee research has focused on environmental stressors such as pesticides, pathogens and diseases. Now a research team led by entomologists at the University of California, Riverside has published a study that focuses on an anthropogenic pollutant: selenium (Se). [More]
New research shows no increased danger for egg allergic children who take flu shots

New research shows no increased danger for egg allergic children who take flu shots

All children should have flu shots, even if they have an egg allergy, and it's now safe to get them without special precautions. This finding is from the latest update on the safety of the flu vaccine for allergic patients, published in the October issue of the Annals of Allergy, Asthma and Immunology, the official journal of the American College of Allergy, Asthma and Immunology. [More]
FDA expands Hizentra administration options for people with primary immunodeficiency

FDA expands Hizentra administration options for people with primary immunodeficiency

CSL Behring announced today that the U.S. Food and Drug Administration has expanded the administration options for Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, to include dosing once every two weeks (biweekly) for people diagnosed with primary immunodeficiency. [More]
Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim and Eli Lilly and Company today announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the safety of the dipeptidyl peptidase-4 inhibitor linagliptin in adults with type 2 diabetes. [More]
Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis. [More]
FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate. [More]
Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer Inc. announced today the company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), received European approval for an expanded indication to include adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae (S. pneumoniae). [More]
EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features. [More]
Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent). [More]
Amedra Pharmaceuticals re-launches single-dose epinephrine auto-injector, Adrenaclick

Amedra Pharmaceuticals re-launches single-dose epinephrine auto-injector, Adrenaclick

Amedra Pharmaceuticals LLC has announced re-launch of Adrenaclick®, a single-dose epinephrine auto-injector, for the emergency treatment of life threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. Adrenaclick® will be available as a two-pack carton in both 0.15 mg and 0.30 mg strengths. [More]